---
title: "On September 25th, LIVZON PHARMA spent CNY 4.9976 million to repurchase 129,300 A shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258830948.md"
description: "According to the Zhitong Finance APP, LIVZON PHARMA announced that it spent CNY 4.9976 million to repurchase 129,300 A-shares on September 25, 2025"
datetime: "2025-09-25T08:41:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258830948.md)
  - [en](https://longbridge.com/en/news/258830948.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258830948.md)
generator: "portal-rs"
---

# On September 25th, LIVZON PHARMA spent CNY 4.9976 million to repurchase 129,300 A shares

According to the Zhitong Finance APP, LIVZON PHARMA (01513) announced that it spent CNY 4.9976 million to repurchase 129,300 A-shares on September 25, 2025

### Related Stocks

- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)

## Related News & Research

- [Livzon MABPharm wins China approval for Lecankitug psoriasis injection](https://longbridge.com/en/news/297167246.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [WUXI APPTEC  Sells 4.23% Stake in WUXI XDC, Cashes In HKD3.9B](https://longbridge.com/en/news/297217460.md)
- [Fosun International grants 990,000 employee share options priced at HK$ 5.41](https://longbridge.com/en/news/297307473.md)
- [How Investors Are Reacting To BeOne Medicines (ONC) First-Line HER2-Positive GEA Immunotherapy Approval](https://longbridge.com/en/news/297146976.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**